Revolution Medicines Stock Performance
| RVMD Stock | USD 38.30 0.75 1.92% |
Revolution Medicines has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 0.79, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Revolution Medicines' returns are expected to increase less than the market. However, during the bear market, the loss of holding Revolution Medicines is expected to be smaller as well. Revolution Medicines right now holds a risk of 2.87%. Please check Revolution Medicines kurtosis, and the relationship between the downside variance and day median price , to decide if Revolution Medicines will be following its historical price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Revolution Medicines are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak primary indicators, Revolution Medicines may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return (1.92) | Five Day Return 0.66 | Year To Date Return (12.95) | Ten Year Return 32.53 | All Time Return 32.53 |
1 | Disposition of 4665 shares by Kelsey Stephen Michael of Revolution Medicines at 44.1853 subject to Rule 16b-3 | 04/25/2025 |
2 | Acquisition by Mark Goldsmith of 97400 shares of Revolution Medicines subject to Rule 16b-3 | 05/02/2025 |
3 | Revolution medicines outlines 2025 focus on RAS inhibitors in key cancer trials | 05/07/2025 |
4 | Revolution Medicines Price Target Reduced by H.C. Wainwright Analyst RVMD Stock News | 05/14/2025 |
5 | Disposition of 2173 shares by Wei Lin of Revolution Medicines at .83 subject to Rule 16b-3 | 06/12/2025 |
6 | Revolution Medicines Gains After FDA Grants Breakthrough Status | 06/23/2025 |
7 | Acquisition by Clyburn Frank of 2806 shares of Revolution Medicines subject to Rule 16b-3 | 06/26/2025 |
8 | Revolution Medicines and Summit Therapeutics Announce Clinical Collaboration RVMD stock news | 06/30/2025 |
9 | Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress | 07/02/2025 |
10 | Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambics ... | 07/09/2025 |
11 | Goldman Sachs Initiates Coverage of Revolution Medicines with Buy Rating RVMD Stock News | 07/15/2025 |
12 | Revolution Medicines Gets Initiated With a New Buy Rating at Goldman Sachs | 07/16/2025 |
| Begin Period Cash Flow | 699.2 M | |
| Total Cashflows From Investing Activities | -554.4 M |
Revolution | Build AI portfolio with Revolution Stock |
Revolution Medicines Relative Risk vs. Return Landscape
If you would invest 3,656 in Revolution Medicines on April 21, 2025 and sell it today you would earn a total of 174.00 from holding Revolution Medicines or generate 4.76% return on investment over 90 days. Revolution Medicines is currently generating 0.1139% in daily expected returns and assumes 2.874% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Revolution, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Revolution Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revolution Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Revolution Medicines, and traders can use it to determine the average amount a Revolution Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0396
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | RVMD | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.87 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Revolution Medicines is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revolution Medicines by adding it to a well-diversified portfolio.
Revolution Medicines Fundamentals Growth
Revolution Stock prices reflect investors' perceptions of the future prospects and financial health of Revolution Medicines, and Revolution Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revolution Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 5.17 B | ||||
| Shares Outstanding | 186.27 M | ||||
| Price To Book | 3.43 X | ||||
| Price To Sales | 9,035 X | ||||
| Gross Profit | (679.95 M) | ||||
| EBITDA | (589.02 M) | ||||
| Net Income | (600.09 M) | ||||
| Cash And Equivalents | 461.43 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 135.84 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 11.16 X | ||||
| Cash Flow From Operations | (557.44 M) | ||||
| Earnings Per Share | (4.01) X | ||||
| Market Capitalization | 7.13 B | ||||
| Total Asset | 2.56 B | ||||
| Retained Earnings | (1.74 B) | ||||
| Working Capital | 2.16 B | ||||
About Revolution Medicines Performance
By analyzing Revolution Medicines' fundamental ratios, stakeholders can gain valuable insights into Revolution Medicines' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revolution Medicines has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revolution Medicines has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (728.15) | (691.74) | |
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.25) | |
| Return On Equity | (0.26) | (0.28) |
Things to note about Revolution Medicines performance evaluation
Checking the ongoing alerts about Revolution Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revolution Medicines help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (600.09 M) with loss before overhead, payroll, taxes, and interest of (679.95 M). | |
| Revolution Medicines currently holds about 461.43 M in cash with (557.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26. | |
| Revolution Medicines has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Revolution Medicines Gets Initiated With a New Buy Rating at Goldman Sachs |
- Analyzing Revolution Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revolution Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Revolution Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revolution Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revolution Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revolution Medicines' stock. These opinions can provide insight into Revolution Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Revolution Stock analysis
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |